

IEC acceptance certificate



आरोग्यं नृणः सम्पदा

सदाचार समिति
Institute Ethics Committee
अखिल भारतीय आयुर्विज्ञान संस्थान , रायपुर (छत्तीसगढ़)
All India Institute of Medical Sciences, Raipur (Chhattisgarh)
Academic Section, 2nd Floor,
Medical College Complex, Gate No. 5
Tatibandh, GE Road, Raipur-492 099 (CG)
Website : www.aiimsraipur.edu.in
Email : iec@aiimsraipur.edu.in
Ethics Committee Registration No.: ECR/1261/Inst/CT/2015/RR-21
NECBHR (DHR) No.: EC/NEW/INST/2020/523

Letter No.: 2797/IEC-AIIMSRPR/2023

Date: 12.04.2023

CERTIFICATE OF APPROVAL

To : **Dr. Murugan T P** (Principal Investigator),
DM, Pediatric Emergency Medicine, AIIMS Raipur
(Guide: Dr. Santosh Kumar Rathia, Assistant Professor,
Department of Trauma and Emergency (Pediatrics),
AIIMS Raipur)

IEC Review Date : 18.03.2023

IEC Proposal No. : AIIMSRPR/IEC/2023/1327

Project Title : Determination of prognostic utility of pSOFA score along
with CRP in children with Septic Shock at Emergency
Department admission.

Remark : Dissertation topic for DM, Pediatric Emergency Medicine

The Institute Ethics Committee, All India Institute of Medical Sciences, Raipur (Chhattisgarh) reviewed and discussed your above referenced project proposal in the sub-committee meeting held on 18.03.2023.

The following documents were reviewed:

1. Covering Letter
2. Research Project Proposal (version 2.0)
3. Case Record Form/Questionnaire (version 1.0)
4. Patient information sheet (English & Hindi) (version 2.0)
5. Consent Form for participants more than 18 years of age (English & Hindi) (version 1.0)
6. LAR Consent Form for participants less than 18 years of age (English & Hindi) (version 1.0)
7. Undertaking regarding GCP guidelines, reporting of SAE and study not being initiated yet.

Page 1 of 3

Certificate of Approval: Proposal No. AIIMSRPR/IEC/2023/1327
Ref: 2797/IEC-AIIMSRPR/2022, dated: 12.04.2023

The following members of Institute Ethics Committee were present at the sub-committee meeting held on 18.03.2023 at 11.00 AM at Academic Section, AIIMS Raipur.

1. Dr. Deepak D'souza, Member (Basic Medical Scientist)
2. Dr. Suprava Patel, Member (Basic Medical Scientist)
3. Dr. Rubik Ray, Member (Clinician)
4. Dr. Ashutosh Tripathi, Member (Clinician AYUSH)
5. Dr. Bhagwant Singh, Member (Philosopher)
6. Dr. Yogendra Keche, Member Secretary

Clear statement of decision reached:

On submission of satisfactory compliance to the issues raised in the IEC sub-committee meetings on 18.03.2023, IEC decided to **approve** above referred project.

As Principal Investigator, you are responsible for fulfilling the following requirements of approval:

1. This approval is valid for two years or duration of the study, whichever is less.
2. All the co-investigators must be kept informed of the status of the project.
3. Changes, amendments, and addendum to the protocol or the consent form, must be submitted to the IEC-AIIMS Raipur for re-review and approval prior to the activation of the changes.
4. Any change of study site, change of investigator/s, termination of study (with reason to do so) should also be informed to IEC-AIIMS Raipur.
5. The IEC proposal number assigned to the project should be cited in any correspondence.
6. Any Serious Adverse Event (SAE) occurring during the course of the study should be reported to the IEC-AIIMS Raipur.
7. New information that becomes available which could change the risk: benefit ratio must be submitted promptly for IEC review.
8. Only approved consent forms are to be used in the enrolment of participants. All consent forms signed by subjects and/or witnesses should be retained on file.


Page 2 of 3

The IEC may conduct audits of all study records, and consent documentation may be part of such audits.

9. IEC-AIIMS Raipur office requires review of an approved study not less than once per 06-month period. **Therefore, a continuing review application must be submitted to the IEC-AIIMS Raipur in order to continue the study beyond the approved period.** Failure to submit a continuing review application in a timely fashion will result in termination of Ethics Committee approval for the study, at which point new participants may not be enrolled and currently enrolled participants must be taken off the study. No separate communication will be sent by IEC-AIIMS Raipur in this regard.
10. The final report of the study must be submitted to IEC-AIIMS Raipur after the completion of the study.

It is, hereby, confirmed that neither you nor any of the study team members have participated in the voting/decision making procedures of the committee.

Sincerely,



Dr. Yogendra N. Keche

Member Secretary
Institute Ethics Committee
All India Institute of Medical Sciences
Raipur-492099 (C.G.)

PARENT INFORMATION SHEET (ENGLISH)

Title: “Determination of prognostic utility of pSOFA in children with Sepsis/Septic Shock and added advantage of quantitative CRP and lactate values at ED presentation”

INVESTIGATORS:

1. Dr. Murugan T P, Senior Resident, Department of Pediatrics, AIIMS, Raipur.
2. Dr. Santosh Kumar Rathia Assistant Professor, Department of Pediatrics, AIIMS, Raipur.
3. Dr. Varun Anand, Assistant Professor, Department of Paediatrics, AIIMS, Raipur.
4. Dr. Anil K Goel, Professor, Head of Paediatrics, AIIMS, Raipur

INTRODUCTION AND PURPOSE

Children present with features suggestive of sepsis and septic shock to our paediatric emergency Medicine will be enrolled in our study and their treatment guidelines will be monitored and treatment plan will be checked as per protocols. This study was entailed mainly for a scoring system to prognosticate the outcome risk factors at the presentation of a child in ER.

ELIGIBILITY TO PARTICIPATE IN THE STUDY

All patients between the age group of 3months – 15years admitted to Pediatric emergency fulfilling the inclusion – exclusion criteria are eligible.

PROCEDURES IN THE STUDY

If you agree to be participants in the study, the basic history and clinical findings will be documented in our proforma and bedside investigations will be performed for assessing infection along with other relevant investigations pertaining to the clinical evidence. The data collected will be handed over to the statistician for analysis to propose a new scoring system.

POTENTIAL RISK INVOLVED

Routine risks involved during sampling along with radiation exposure due to Xrays / CT scans are present but will only be done if clinically indicated. This study imparts no additional risks to the child.

POTENTIAL BENEFITS OF PARTICIPATION

By participating in the study, you will help in developing a new scoring system in the pediatric age group .

CONFIDENTIALITY

All the information obtained will be maintained confidential. However, the information obtained will be used in the purpose of this study without disclosing the identity of the individual.

WHAT WILL HAPPEN IF YOU DON'T WANT TO CARRY ON WITH THE STUDY?

You are free to exit from the study as per the consent decision and treatment will be carried as per the standard protocol

APPROVALS AND CONTACT

The study will be approved by the Ethical Review Board, AIIMS, Raipur. Any query regarding the study can be clarified by contacting

Dr. Murugan: 9790607095. Email ID: murugantp007@gmail.com Guide: Dr. Santosh Kumar Rathia: 9891611996

DETAILS OF INSTITUTE ETHICS COMMITTEE:

Name of Ethics Committee: Institute Ethics Committee- AIIMS, Raipur Name of Member Secretary: Dr. Yogendra Keche Phone No: 0771-2577231 Ethics Committee Email: iec@aiimsraipur.edu.in

Assent Form for participants of age 12 – 18 years (Form 3C)
12 से 18 वर्ष की उम्र के प्रतिभागियों के लिए सहमति फॉर्म (फॉर्म 3सी)

Principal Investigator/ मुख्य शोधकर्ता :

Participant's Name/ प्रतिभागी का नाम :

Title of the project:

परियोजना का शीर्षक:

We are doing a research study. I am [you or your representative's name].

We are doing this study to find out [write the purpose of your study].

We are asking you to take part in this study because you [give reason]

But we will only take you if you allow us. If you do not want to do so your treatment will continue as usual. If you decide to take part now, but wish to discontinue later, you can tell us, and we will take you out of the study.

Once you agree to take part, you will have to [mention procedures that will be done]

These procedures can [write about risks/discomforts]

It is possible that the study will help you feel better. It can also occur that you do not get any benefit but the information we get from you may help other children in future.

We have asked your parents [or guardian] their permission and it is all right with them.

Do not hesitate to ask questions. You can also ask us about anything later if there are no questions right now.

हम एक शोध अध्ययन कर रहे हैं। मैं (आप या आपके प्रतिनिधि का नाम) हूँ। हम इस अध्ययन को (अपने अध्ययन का उद्देश्य लिखें) का पता लगाने के लिए कर रहे हैं। हम आपको इस अध्ययन में भाग लेने के लिए कह रहे हैं, क्योंकि (कारण बताईये)।

अगर आप हमें अनुमति देते हैं, तो ही हम आपको अनुसंधान में शामिल करेंगे। यदि आप ऐसा नहीं चाहते हैं तो आपका उपचार सामान्य रूप से जारी रहेगा। यदि आप अभी भाग लेने का फैसला करते हैं, लेकिन बाद में बंद करना चाहते हैं, तो आप हमें बता सकते हैं, और हम आपको अध्ययन से बाहर ले जाएंगे।

एक बार जब आप भाग लेने के लिए सहमत हो जाते हैं, तो आपको (प्रक्रियाओं का उल्लेख करें जो किया जाएगा) इन प्रक्रियाओं में (जोखिम/असुविधाओं के बारे में लिखें) हो सकता है।

यह संभव है कि अध्ययन आपको बेहतर महसूस करने में मदद करेगा। यह भी हो सकता है कि आपको कोई लाभ नहीं मिले, लेकिन आपके द्वारा प्राप्त की जाने वाली जानकारी भविष्य में अन्य मरीजों को सहायक हो सकती है।

हमने आपके माता-पिता (या अभिभावक) से उनकी अनुमति मांगी है और वह इसके लिए राजी है।

प्रश्न पूछने में संकोच नहीं करें। यदि अभी कोई सवाल नहीं है तो आप हमें बाद में कुछ भी पूछ सकते हैं।

Child's signature/thumb impression: बच्चे के हस्ताक्षर/अंगूठे की छाप:

I have been explained about the study and I agree to take part in it.

मुझे अध्ययन के बारे में समझाया गया है और मैं इसमें भाग लेने के लिए सहमत हूँ।

Child's Name/ बच्चे का नाम :

Date/ तिथि :

Statement by Researcher/person taking consent: शोधकर्ता/सहमति लेने वाले व्यक्ति का वक्तव्य विवरण :

I have accurately read out the information sheet to the potential participant, and to the best of my ability made sure that the participant understands the purpose of study.

I confirm that the participant was given an opportunity to ask questions about the study, and all the questions asked by the participant have been answered correctly and to the best of my ability.

I confirm that the individual has not been coerced into giving assent, and the consent has been given freely and voluntarily.

मैंने संभावित प्रतिभागी को सूचना पत्रक को सटीक रूप से पढ़ कर बताया है, और अपनी योग्यतम क्षमता से सुनिश्चित किया है कि प्रतिभागी अध्ययन के उद्देश्य को समझता हैं।

मैं पुष्टि करता/करती हूँ कि प्रतिभागी को अध्ययन के बारे में प्रश्न पूछने का अवसर दिया गया था और प्रतिभागी द्वारा पूछे गए सभी प्रश्नों का सही उत्तर मेरी सर्वोत्तम क्षमता अनुसार दिया गया है।

मैं पुष्टि करता/करती हूँ कि प्रतिभागी को सहमति देने में मजबूर नहीं किया गया है और सहमति स्वतंत्र रूप एवं स्वेच्छा से प्रदान की गई है।

Name of Researcher/person taking consent:

शोधकर्ता/सहमति लेने वाले व्यक्ति का नाम:

Signature of Researcher/person taking consent:

शोधकर्ता/सहमति लेने वाले व्यक्ति का हस्ताक्षर

Date/दिनांक:

Place/स्थान:

CASE PROFORMA

Case No:	CR No:
Name of Participant:	Age /Sex:
Father's name:	Weight/Height:
Phone number:	
Sepsis / Septic shock:	
Brief clinical history and background	

Vital parameters		Centiles for age
Heart rate		
Respiratory Rate		
Blood pressure		
Saturation		
Temp		
CRT		
Central /peripheral pulses		
GCS		
Pupils		

Co-morbidity (chronic lung/ liver/ heart/ kidney/ CNS/ Neuromuscular)	
Malnutrition/ Malignancy/ autoimmune/ auto inflammatory disorders/ SCD/ immunosuppressed states	
History of prior hospitalization	
Skin infections/ Soft tissue infections/ deep infections/ pneumonia/meningitis	
Sepsis related resuscitation parts: fluid bolus	
Early identification of Septic Shock:	
Fluid resuscitations and responsiveness:	
Point of care ultrasound in ED:	
Inotropic support started when / after how many bolus	
Early antibiotics administration:	
Inotropic supports and requirements after boluses:	
Intubation/CPAP/HFNC	
Shock index:	
CRP:	
Procalcitonin:	
Lactate	
Blood culture	
Length of hospital stay	
ED duration time	
PICU/HDU length of stay_____	
Follow up, Discharged alive/ mortality/LAMA	
Cause of mortality	
Final Diagnosis:	

Table 1. Pediatric Sequential Organ Failure Assessment Score

Variables		Score				
		0	1	2	3	4
Respiratory	PaO ₂ :FiO ₂ or	≥400	300-399	200-299	100-199 with respiratory support	<100 with respiratory support
	SpO ₂ :FiO ₂	≥292	100-149	50-99	20-49	<20
Coagulation	Platelet count (x10 ³ /μL)	≥150	100-149	50-99	20-49	<20
Hepatic	Total bilirubin (mg/dL)	<1.2	1.2-1.9	2.0-5.9	6.0-11.9	>12.0
Cardiovascular - MAP by age group or vasoactive infusion, mmHg or μg/kg/min	<1 mo	≥46	<46			
	1-11 mo	≥55	<55			
	12-23 mo	≥60	<60	Dopamine hydrochloride ≤ ordobutamine hydrochloride (any)	Dopamine hydrochloride >5or epinephrine	Dopamine hydrochloride >15or epinephrine
	24-59 mo	≥62	<62		≤0.1or norepinephrine bitartrate ≤0.1	>0.1or norepinephrine bitartrate >0.1
	60-143 mo	≥65	<65			
	144-216 mo	≥67	<67			
	>216 mo	≥70	<70			
Neurologic	Glasgow coma score	15	13-14	10-12	6-9	<6
Renal - Creatinine by age group	<1 mo	<0.8	0.8-0.9	1.0-1.1	1.2-1.5	≥1.6
	1-11 mo	<0.3	0.3-0.4	0.5-0.7	0.8-1.1	≥1.2
	12-23 mo	<0.4	0.4-0.5	0.6-1.0	1.1-1.4	≥1.5
	24-59 mo	<0.6	0.6-0.8	0.9-1.5	1.6-2.2	≥2.3
	60-143 mo	<0.7	0.7-1.0	1.1-1.7	1.8-2.5	≥2.6
	144-216 mo	<1.0	1.0-1.6	1.7-2.8	2.9-4.1	≥4.2
	>216 mo	<1.2	1.2-1.9	2.0-3.4	3.5-4.9	≥5

Other relevant investigations	
Haemoglobin	
Total counts and differential counts	
Platelet count	
Creatinine/ urea	
Liver function test	
Sodium/ Potassium	
Urine RM/ culture	
Other any specific to disease	

Master excels sheet

1	SERIAL NO:	CR Number	AGE	SEX	boy	CO Morbi	Co-Morbi	SAM1	no	p5OFA	SC	p5OFA	AT	CRP	0	CRP	48	PROCalcit	PRO	48	Lactate	0	Lactate	48	Vasoactive	Mech	Ven	LOS	in	PIC	alive	1/De	SHOCK	IN	haemoglo	total	coun	platelet	total	bliri	creat						
2	1	2.29142E+14	7	1		0	NIL		1	11	12	32.5	38	11	14.5	34	12	40	7	14	1	0.5	7.3	38000	257000	1.1	1.1																				
3	2	2.29142E+14	15	1		1	Post Ence		1	8	11	42	14	1.8	1.3	8	14	40	7	11	1	1.4	8.3	18000	180000	1.1	1.1																				
4	3	2.29142E+13	4	1		0	NIL		1	11	13	42.6	153	2.3	8.4	8.2	14	40	3	10	1	1.3	6.3	36000	160000	1.3	1.2																				
5	4	2.29142E+13	124	1		1	HEM		0	12	14	36	52.5	1.2	1.8	12	14	40	6	14	1	1.8	8.3	15800	180000	1.1	1.1																				
6	5	2.29142E+13	28	1		0	NIL		0	7	9	15.8	26	1.3	0.9	2.8	1.66	20	3	6	1	0.6	9.3	15800	180000	0.9	0.7																				
7	6	2.29142E+14	156	0		1	SLE		0	7	11	54.6	138	1.5	2.3	2.44	5.4	20	3	8	1	0.5	9.3	18400	190000	1.1	1.1																				
8	7	2.29142E+14	18	1		0	NIL		0	9	10	23.6	28.4	1.1	1.1	2.47	1.66	20	3	8	1	0.8	8.4	14440	240000	0.8	0.7																				
9	8	2.29142E+14	60	1		1	wilson		0	14	16	85.1	144.6	1.7	10.2	6.4	12.4	60	8	8	0	1.1	11.2	18800	165000	0.7	0.9																				
10	9	2.29142E+14	52	1		1	CHD		1	11	13	165.3	197.4	11.5	11.8	6.3	7.4	50	3	14	1	1.4	11.1	23000	440000	0.8	0.67																				
11	10	2.29142E+14	75	0		1	craniopha		0	10	14	142.4	168	3.4	4.8	30	11.3	70	10	10	0	1.4	10.4	18000	244400	0.8	1.1																				
12	11	2.29142E+14	148	1		1	SLE		0	14	18	114.5	247	14.6	18.4	5.4	8.4	70	12	12	0	1.3	9.6	24000	154400	1.2	1.4																				
13	12	2.29142E+14	16	1		1	ACHD		1	11	14	48.4	112	1.1	4.5	6.4	8.4	60	10	10	0	1.1	7.2	16200	184000	1.1	0.6																				
14	13	2.29142E+14	8	0		0	NIL		0	8	13	46.4	44.6	1.1	2.3	4.5	6.4	60	5	14	1	0.6	8.4	14880	156000	0.8	0.9																				
15	14	2.29142E+14	164	1		1	leprosy		0	11	15	38.4	112	1.5	4.2	8.2	14.2	60	3	3	0	1.3	9.4	16800	168000	1.2	0.9																				
16	15	2.29142E+14	10	0		1	Portal hyc		0	4	3	14	16.4	1.4	2.1	4.8	2.3	30	5	11	1	0.6	8.4	14500	112000	0.9	0.8																				
17	16	2.29142E+14	39	1		1	GDO/Epik		1	8	10	44.6	58.6	1.5	6.8	5.4	4.6	60	6	6	0	1.6	8.8	14000	165000	1.1	0.9																				
18	17	2.29142E+14	180	0		0	NIL		0	14	16	154	164.4	11.4	44.3	11	9.4	80	6	6	0	1.6	9.1	36000	144000	3.1	1.4																				
19	18	2.29142E+14	36	1		0	NIL		0	6	6	18	24.2	1.8	1.8	3.2	1.66	20	3	7	1	0.4	8.4	14000	186000	1.1	0.6																				
20	19	2.29142E+14	86	0		1	thalassem		0	8	10	48	36.4	6.4	1.4	4	2.3	20	3	7	1	0.4	6.4	13000	256000	1.4	0.6																				
21	20	2.29142E+14	88	1		1	TBI		0	9	11	36.4	44.2	1.1	1.1	3.6	2.8	40	5	8	1	0.4	8.4	14000	254400	1.1	0.8																				
22	21	2.29142E+14	52	1		1	CHD		0	9	11	142.6	222.2	5.3	2.1	11.2	8.1	50	6	8	1	0.5	12.4	13800	244000	1.1	0.6																				
23	22	2.29142E+14	148	1		1	hirsutpru		0	6	8	285.4	140.4	3.2	3.4	4.2	3.8	30	5	9	1	0.6	11.3	14500	240000	1.1	0.6																				
24	23	2.29142E+14	9	1		1	Cong Hyde		0	2	6	14.2	11.2	0.8	0.8	3.4	2.1	10	2	6	1	0.4	10.3	13800	252000	0.8	0.6																				
25	24	2.29142E+14	144	0		0	NIL		0	9	12	36.4	48	2.4	1.6	3.8	4.4	20	0	8	1	0.6	8.4	3400	48000	1.3	0.8																				
26	25	2.29142E+14	144	1		0	NIL		0	11	13	14.6	22.5	1.3	0.9	6.4	2.4	30	2	6	1	0.4	11.2	11200	254000	0.8	0.6																				
27	26	2.29142E+14	74	1		1	ALL		0	12	17	142	197.4	13.4	18.2	3.8	1.6	80	4	8	1	0.6	10.9	14000	188000	1.1	0.8																				
28	27	2.29142E+14	145	0		0	NIL		0	16	18	188.4	168.4	16.8	16.8	10.4	14.5	110	2	2	0	1.7	10.5	13800	168000	1	1.4																				
29	28	2.29142E+14	132	1		1	severe de		0	11	13	186.4	116.4	23.6	4.6	6.4	2.8	70	0	8	1	0.6	9.2	8400	38000	1.4	0.9																				
30	29	2.29142E+14	132	0		1	CKD		0	14	15	152.3	182.6	14.2	13.6	8.4	4.8	80	8	8	0	1.4	9.4	16800	210000	0.9	13.1																				
31	30	2.29142E+14	7	0		1	CHD		0	10	12	152.6	188.6	14.2	16.5	8.1	4.8	80	2	2	0	1.4	12.5	13000	188000	1.1	0.9																				
32	31	2.29142E+14	3	0		0	NIL		0	12	16	54.1	88.3	11.2	32.1	11.2	8.4	80	3	3	0	1.6	10.9	14000	188000	1.1	0.8																				
33	32	2.29142E+14	156	1		1	adrenal in		0	1	1	4.3	2.4	0.5	0.5	3.2	1.4	20	0	4	1	0.6	10.5	13800	188000	1.1	0.6																				
34	33	2.29142E+14	88	1		1	adrenal in		0	11	14	144	138.6	11.8	11.8	10	8.4	80	4	4	0	1.4	10.3	14000	188000	0.6	0.8																				
35	34	2.29142E+13	124	1		1	SLE		0	2	6	32.6	14.8	1.1	1.2	3.6	1.2	30	0	4	1	0.6	11.3	4800	142000	1.1	0.6																				
36	35	2.29142E+14	36	1		1	Febrile stu		0	12	17	142	197.4	13.4	18.2	3.8	1.6	80	4	8	1	0.6	10.6	3800	168000	1	0.6																				
37	36	2.29142E+14	26	1		0	NIL		0	16	16	153.6	148.4	23.6	16.8	8.2	6.2	90	4	4	0	1.5	9.8	15000	166000	1.1	0.7																				
38	37	2.29142E+13	126	1		1	severe de		0	3	3	18.4	24.5	1.2	1.3	4.2	1.65	0	0	5	1	0.6	14.3	2600	36000	1.4	0.8																				
39	38	2.29142E+14	108	1		1	AES		0	4	6	142.6	158	1.3	1.2	4.1	0.8	30	3	6	1	0.5	10.3	14000	245000	1.1	0.8																				
40	39	2.29142E+14	144	0		0	NIL		0	1	2	112.2	38.4	3.2	1.8	4.5	1.2	0	0	3	1	0.5	11.2	15400	246000	1	0.6																				
41	40	2.29142E+14	15	0		1	HIE sequa		0	3	4	17.2	14.8	1	0.8	3.6	2.8	30	4	4	1	0.4	10.9	13200	248000	1.1	0.6																				
42	41	2.29142E+14	38	0		0	NIL		0	13	18	168.4	184.4	1.8	1.8	4.8	3.6	80	4	4	0	1.6	11.2	14800	188000	0.9																					

126	2.29142E+14	84	1	0	CLD	0	17	14	48.4	112.6	11.6	29.6	6.2	5.8	80	3	3	0	1.6	6.8	19600	228000	15.2	0.9
127	2.29142E+14	48	0	0	CLD	0	8	8	16.8	182.6	11.6	26.3	5.8	6.2	80	3	3	0	1.4	8.4	35000	268000	23.1	0.9
128	2.29142E+14	144	0	0	CLD	0	8	8	15.6	168.4	24.6	112.6	5.4	6.2	80	2	2	0	1.4	8.4	19600	147000	24.6	1.3
129	2.29142E+14	88	1	0	CLD	0	8	10	16.8	112.6	11.2	16.5	3.6	4.6	80	2	2	0	1.4	6.4	18400	126800	23.2	1.3
130	2.29142E+14	64	1	0	SLE	0	8	8	14.2	18.4	3.6	11.2	4.6	8.4	30	3	10	1	0.6	8.4	19600	284000	1.1	0.9
131	2.29142E+14	58	1	0	SLE	0	6	8	25.6	64.6	11.2	13.6	4.6	1.2	30	3	3	0	1.5	6.9	18400	236000	1.1	0.9
132	2.29142E+14	42	0	0	SLE	1	8	10	9	11.2	1.6	2.3	1.2	1.8	30	2	10	1	0.6	8.4	24600	184000	1.1	0.6
133	2.29142E+14	112	0	0	SLE	0	6	6	15.6	25.6	11.2	13.2	4.5	6.8	40	3	10	1	0.4	6.9	16800	224000	1.1	0.9
134	2.29142E+14	156	1	0	SLE	0	8	10	18.4	44.6	12.1	16.2	4.6	3.9	60	3	3	0	1.6	7.4	18400	184000	1.1	0.6
135	2.29142E+14	185	1	0	SLE	0	6	12	16.5	58.4	11.2	14.2	1.6	6.4	40	2	10	1	0.6	6.9	18400	168000	1.1	0.9
136	2.29142E+14	185	0	0	SLE	0	8	14	14.6	64.3	3.6	14.6	1.9	4.8	30	3	10	1	0.4	7.4	16800	268000	1.1	0.6
137	2.29142E+14	147	0	0	SLE	0	6	8	25.6	48.4	11.3	18.4	4.6	6.9	60	4	4	1	1.6	6.9	18400	248000	1.1	0.6
138	2.29142E+14	168	1	0	TBI	0	8	8	11.3	36.6	16.2	18.6	1.6	6.4	30	2	6	1	0.6	7.2	16800	284000	1.1	0.9
139	2.29142E+14	184	0	0	TBM	0	4	6	112.6	48.4	11.2	19.4	1.6	8.4	60	6	6	1	1.6	6.9	18000	248000	1.6	0.6
140	2.29142E+14	168	1	0	TBM	0	2	4	25.6	36.6	11.2	18.4	1.6	4.6	30	3	9	1	0.6	7.4	16800	184000	1.1	0.9
141	2.29142E+14	144	0	0	SLE	0	6	6	11.6	145.6	3.2	19.4	6.1	4.6	60	4	4	1	1.4	7.4	19600	284000	1.1	0.9
142	2.29142E+14	32	1	0	CKD	1	6	10	18.6	42.6	11.2	19.6	1.6	4.6	60	3	3	1	1.6	7.4	18400	169000	1.1	0.6
143	2.29142E+14	16	0	0	CKD	1	6	10	18.6	42.6	18.4	26.4	1.6	6.4	60	4	4	1	1.6	6.9	14600	184000	1.1	0.6
144	2.29142E+14	18	1	0	CKD	1	6	15	112.5	188.6	14.5	69.4	1.9	6.4	60	3	3	1	1.6	7.4	16800	194000	1.2	0.6
145	2.29142E+14	24	0	0	MALARIA	1	8	8	11.2	88.6	11.2	84.6	3.6	4.9	30	2	6	1	0.6	8.4	15400	224000	1.2	0.6
146	2.29142E+14	36	1	0	SLE	1	2	10	13.6	69.4	11.2	16.4	3.4	4.9	60	3	3	1	1.4	9.2	36000	194000	1.2	0.9
147	2.29142E+14	45	0	0	PID	1	5	12	14.6	112.6	3.1	68.4	1.4	6.4	30	3	3	1	1.6	8.4	16800	228000	1.1	0.9
148	2.29142E+14	58	1	0	CKD	1	6	16	28.6	187.6	1.6	36.4	3.4	6.4	60	2	5	1	0.8	9.2	18400	136000	1.1	0.6
149	2.29142E+14	64	0	0	SLE	0	8	16	39.6	212.6	15.4	67.4	3.5	6.4	60	3	3	1	1.6	8.4	16800	184000	1.1	0.9
150	2.29142E+14	74	1	0	CKD	0	6	8	14.8	62.6	1.6	36.4	1.1	6.4	30	3	10	1	0.5	6.9	19600	224000	1.2	0.9
151	2.29142E+14	66	0	0	SLE	0	6	8	11.2	24.6	11.2	36.2	6.2	4.9	40	4	0	1	0.4	4.8	4900	184000	1.3	0.9
152	2.29142E+14	68	1	0	AES	0	6	8	11.2	16.4	11.2	13.2	4.2	3.6	30	2	4	1	0.6	6.9	31000	168000	1.3	0.9
153	2.29142E+14	24	1	0	AES	0	6	6	12.3	64.6	13.6	13.9	4.2	6.4	60	2	10	1	0.4	6.8	14000	168000	1.2	0.9
154	2.29142E+14	44	0	0	1AES	1	6	6	12.3	16.5	1.6	12.3	3.6	4.6	60	2	10	1	0.6	6.9	18400	168400	1.1	0.9
155	2.29142E+14	36	0	0	CLD	1	8	12	16.5	28.6	6.4	16.5	6.2	4.6	30	2	6	1	0.5	8.4	42600	68000	15.2	1.3
156	2.29142E+14	54	1	0	TSS	0	6	12	46.5	24.6	2.6	24.6	2.6	6.4	80	3	8	0	0.6	6.4	39500	184000	1.2	0.9
157	2.29142E+14	66	1	0	NO	0	6	8	16.8	36.4	1.3	5.6	1.6	3.9	20	2	6	1	0.6	9.4	18400	264000	1.2	0.9
158	2.29142E+14	84	1	0	NO	1	6	8	11.2	36.4	1.9	2.6	3.6	4.5	30	2	10	1	0.6	6.9	15800	228000	1.2	0.9
159	2.29142E+14	64	0	0	SLE	1	8	8	11.6	28.6	13.6	16.3	6.4	1.9	30	2	6	1	0.6	7.4	18400	168000	1.2	0.6
160	2.29142E+14	112	1	1	CKD	1	6	12	69.4	184.6	16.6	29.6	6.4	10.5	80	6	6	0	1.1	7.9	16800	194000	1.6	2.3
161	2.29142E+14	36	1	1	severe de	1	6	6	11.2	38.4	11.2	13.6	3.6	6.2	40	3	10	1	0.6	12.9	3.6	19000	1.1	0.9
162	2.29142E+14	44	0	0	1EM	1	6	6	11.6	38.4	11.2	36.4	6.2	6.9	80	6	6	0	0.6	9.4	14800	296000	1.1	0.8
163	2.29142E+14	38	1	1	1EM	1	6	6	13.6	28.6	1.9	11.3	1.2	8.3	60	6	14	1	0.6	7.9	14600	269000	1.2	0.9
164	2.29142E+14	24	0	0	1Pneumon	1	6	12	44.6	178.6	31.6	4.2	3.2	4.9	80	6	6	0	0.6	8.4	19600	282000	1.1	0.9
165	2.29142E+14	39	1	1	Pneumon	1	8	10	38.4	168.4	31.6	43.6	3.6	4.9	80	3	3	0	0.6	8.4	26800	294000	1.2	0.6
166	2.29142E+14	84	0	0	1Pneumon	0	6	8	11.6	24.6	1.9	6.5	1.9	3.5	30	3	10	1	0.4	6.4	18400	196000	1.1	0.9
167	2.29142E+14	102	1	1	1ALL	1	6	10	36.6	184.6	13.6	29.6	3.6	4.9	80	3	3	0	0.9	6.2	1800	12000	1.3	1.6
168	2.29142E+14	58	1	1	ALL	0	6	10	36.4	112.6	11.3	18.6	3.2	1.8	60	6	10	1	0.9	6.4	1800	11000	1.3	0.9

168	2.29142E+14	58	1	1	ALL	0	6	10	36.4	112.6	11.3	18.6	3.2	1.8	60	6	10	1	0.9	6.4	1800	11000	1.3	0.9
169	2.29142E+14	44	1	1	ALL	0	4	6	11.2	13.6	9.4	11.6	1.9	3.4	40	2	10	1	1.1	8.1	1400	6000	1.1	0.9
170	2.29142E+14	112	1	1	ALL	0	6	8	11.3	39.4	11.3	13.2	3.6	4.6	40	2	8	1	0.9	6.4	1300	8000	1.3	0.9
171	2.29142E+14	58	0	1	ALL	0	6	8	11.3	24.6	1.9	15.6	1.6	4.2	60	2	9	1	0.9	5.4	2990	6000	1.1	0.9
172	2.29142E+14	42	1	1	ALL	0	6	8	18.9	145.6	11.3	26.5	4.5	5.4	80	2	10	1	0.8	5.4	1900	11000	1.1	0.9
173	2.29142E+14	64	1	1	ALL	0	6	6	11.6	64.5	11.6	13.6	4.6	3.9	40	2	4	1	0.8	6.4	16400	19000	1.1	0.9
174	2.29142E+14	84	1	1	wilson	0	6	8	11.6	28.4	11.6	19.6	6.2	4.9	60	2	9	1	0.6	9.1	18400	284000	1.1	0.9
175	2.29142E+14	102	1	1	wilson	1	6	8	11.6	26.4	11.6	13.4	6.8	4.2	60	2	10	1	0.5	9.1	18400	268000	1.1	0.6
176	2.29142E+14	84	0	0	1ACHD	1	6	6	16.5	112.6	13.2	25.6	4.8	11.6	80	3	3	0	1.1	8.1	16800	186000	1.1	0.9
177	2.29142E+14	14	0	0	1ACHD	1	6	6	11.6	28.4	16.4	26.4	4.9	6.4	60	3	9	1	0.6	9.4	16800	244000	1.1	0.9
178	2.29142E+14	8	1	1	ACHD	1	6	8	11.6	23.6	15.3	18.4	1.9	2.3	60	3	10	1	0.5	6.9	16800	156000	1.1	0.9
179	2.29142E+14	8	1	1	ACHD	1	6	8	10.6	23.6	11.6	11.6	1.6	2.6	40	3	10	1	0.6	6.9	18400	168000	1.1	0.9
181	2.29142E+14	14	1	1	ACHD	1	6	10	25.6	26.4	3.6	14.6	4.6	3.6	60	2	2	1	0.9	8.4	36000	295000	1.1	0.9
182	2.29142E+14	16	1	1	ACHD	1	6	10	26.6	132.6	12.3	28.6	4.6	2.6	80	9	9	0	1.2	9.4	24000	168000	1.1	0.6
183	2.29142E+14	12	0	0	ACHD	1	6	12	32.6	24.6	3.4	1.4	3.4	1.6	60	2	10	1	0.9	9.4	18400	146000	1.1	0.9
184	2.29142E+14	16	1	1	ACHD	1	6	8	12.6	25.6	11.3	13.2	6.2	8.4	60	2	10	1	0.5	6.9	18400	254000	1.1	0.6
185	2.29142E+14	18	0	0	ACHD	1	6	8	12.6	14.6	1.6	2.6	1.6	2.6	60	2	10	1	0.6	8.4	19600	254000	1.1	0.9
186	2.29142E+14	24	1	1	ACHD	1	6	8	11.6	28.6	1.6	2.3	1.9	2.4	30	3	10	1	0.5	9.6	18400	254000	1.1	0.6
187	2.29142E+14	14	1	0	1CHD	1	6	8	13.6	24.6	1.6	4.8	6.2	4.6	30	3	10	1	0.6	9.6	18400	245000	1.1	0.9
188	2.29142E+14	16	0	0	1CHD	1	6	10	13.6	28.4	0.6	10.4	6.5	10.4	60	3	10	1	0.6	9.6	18400	245000	1.1	0.9
189	2.29142E+14	18	0	0	1ACHD	1	8	12	15.6	25.6	1.6	2.6	4.6	2.6	30	3	10	1	0.6	9.4	18400	256000	1.1	0.9
190	2.29142E+14	6	1	1	ACHD	1	8	14	11.6	13.6	1.6	3.6	3.6	4.5	40	3	10	1	0.6	9.4	16800	248000	1.1	0.9
191	2.29142E+14	8	1	1	ACHD	1	8	12	15.6	24.6	12.6	18.4	6.2	4.5	30	4	4	1	0.9	9.4	18400	254000	1.1	0.9
192	2.29142E+14	10	1	1	ACHD	1	8	12	16.5	84.6	1.6	5.5	6.5	1.9	30	4	10	1	0.6	8.4	24800	195000	1.1	0.9
193	2.29142E+14	11	1	1	ACHD	1	8	12	13.4	25.6	1.3	6.1	3.6	3.6	45	6	10	1	0.6	8.4	24800	256000	1.1	0.9
194	2.29142E+14	12	1	1	ACHD	1	6	12	11.6	25.6	3.4	11.6	3.6	4.5	40	2	10	1	0.6	8.4	18400	184000	1.1	0.9
195	2.29142E+14	11	0	0	1ACHD	1	6	12	13.6	26.8	1.4	3.6	4.2	6.8	30	2	10	1	0.6	9.4	18400	184000	1.1	0.9
196	2.29142E+14	12	1	1	ACHD	1	8	8	25.6	13.6	25.2	1.6	3.2	4.8	30	2	2	1	0.6	8.4	25400	195000	1.1	0.9
197	2.29142E+14	16	0	0	1CD	1	6	11.6	14.6	13.6	1.9	2.3	2.3	20	1	10	1	0.9	5.6	24800	198800	26.3	3.2	
198	2.29142E+14	26	0	0	1ACHD	1	6	18.6	24.6	13.6	5.5	4.2	6.2	40	2	10	1	0.6	7.8	18400	245000	1.1	0.9	
199	2.29142E+14	36	0	0	1SCRUBTYI	1	8	8	13.6	24.6	13.6	1.5	1.6	6.2	60	2	10	1	0.6	7.8	18400	254000	1.1	0.6
200	2.29142E+14	14	1	1	ACHD	1	4	6	11.6	25.6	1.3	1.6	3.2	1.6	40	0	9	1	0.6	7.9	16800	245000	1.1	0.9
201	2.29142E+14	26	1	1	ACHD	1	4	6	11.6	25.6	1.2	1.3	2.3	4.6	40	0	4	1	0.6	7.9	18400	245000	1.1	0.9
202	2.29142E+14	16	1	1	ACHD	1	4	6	11.6	21.6	0.6	8.4	2.3	30	0	1	1	0.6	8.4	19600	245000	1.1	0.9	
203	2.29142E+14	18	1	1	ACHD	1	4	6	15.6	13.6	6.1	16.4	1.9	1.9	20	10	10	1	0.6	7.8	19600	196000	1.1	0.9
204	2.29142E+14	24	1	1	ACHD	1	4	6	11.3	15.4	6.4	14.6	3.4	4.5	30	0	14	1	0.6	6.4	14000	248000	1.1	0.9
204	2.29142E+14	14	0	1	ACHD	1	4	6	11.6	24.6	6.4	11.6	2.6	4	30	1	11	1	0.4	6.9	18400	254000	1.1	0.9